Recchia J[au] - Search Results

Year	Number of Results
1981	1
1982	1
1991	1
1992	2
1995	3
1996	1
1997	1
1998	2
2022	0

1

DS-1, a modified Quillaja saponin, enhances ocular and nasal absorption of insulin.

Pillion DJ, Recchia J, Wang P, Marciani DJ, Kensil CR. Pillion DJ, et al. Among authors: recchia j. J Pharm Sci. 1995 Nov;84(11):1276-9. doi: 10.1002/jps.2600841104. J Pharm Sci. 1995. PMID: 8587042

2

A semisynthetic Quillaja saponin as a drug delivery agent for aminoglycoside antibiotics.

Recchia J, Lurantos MH, Amsden JA, Storey J, Kensil CR. Recchia J, et al. Pharm Res. 1995 Dec;12(12):1917-23. doi: 10.1023/a:1016235705448. Pharm Res. 1995. PMID: 8786966

3

Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.

Newman MJ, Wu JY, Gardner BH, Munroe KJ, Leombruno D, Recchia J, Kensil CR, Coughlin RT. Newman MJ, et al. Among authors: recchia j. J Immunol. 1992 Apr 15;148(8):2357-62. J Immunol. 1992. PMID: 1373166

4

Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, Beltz GA, Newman GW, Newman MJ. Wu JY, et al. Among authors: recchia j. J Immunol. 1992 Mar 1;148(5):1519-25. J Immunol. 1992. PMID: 1538134

5

Structure-function relationship among Quillaja saponins serving as excipients for nasal and ocular delivery of insulin.

Pillion DJ, Amsden JA, Kensil CR, Recchia J. Pillion DJ, et al. Among authors: recchia j. J Pharm Sci. 1996 May;85(5):518-24. doi: 10.1021/js9504651. J Pharm Sci. 1996. PMID: 8742944

6

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function.

Soltysik S, Wu JY, Recchia J, Wheeler DA, Newman MJ, Coughlin RT, Kensil CR. Soltysik S, et al. Among authors: recchia j. Vaccine. 1995;13(15):1403-10. doi: 10.1016/0264-410x(95)00077-e. Vaccine. 1995. PMID: 8578817

7

Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.

Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, Coughlin RT, Powell MF. Newman MJ, et al. Among authors: recchia j. Vaccine. 1997 Jun;15(9):1001-7. doi: 10.1016/s0264-410x(96)00293-9. Vaccine. 1997. PMID: 9261947

8

Major antigenic proteins of the agent of human granulocytic ehrlichiosis are encoded by members of a multigene family.

Murphy CI, Storey JR, Recchia J, Doros-Richert LA, Gingrich-Baker C, Munroe K, Bakken JS, Coughlin RT, Beltz GA. Murphy CI, et al. Among authors: recchia j. Infect Immun. 1998 Aug;66(8):3711-8. doi: 10.1128/IAI.66.8.3711-3718.1998. Infect Immun. 1998. PMID: 9673253 Free PMC article.

9

Enhancement of intestinal model compound transport by DS-1, a modified Quillaja saponin.

Chao AC, Nguyen JV, Broughall M, Recchia J, Kensil CR, Daddona PE, Fix JA. Chao AC, et al. Among authors: recchia j. J Pharm Sci. 1998 Nov;87(11):1395-9. doi: 10.1021/js9800735. J Pharm Sci. 1998. PMID: 9811496

10

Development of a genetically engineered vaccine against feline leukemia virus infection.

Kensil CR, Barrett C, Kushner N, Beltz G, Storey J, Patel U, Recchia J, Aubert A, Marciani D. Kensil CR, et al. Among authors: recchia j. J Am Vet Med Assoc. 1991 Nov 15;199(10):1423-7. J Am Vet Med Assoc. 1991. PMID: 1666096

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results